Regeneron Announces Presentation at the 10th Annual Needham Healthcare Conference

TARRYTOWN, N.Y., March 30, 2011 /PRNewswire/ — Regeneron
Pharmaceuticals, Inc. (Nasdaq:
REGN) will webcast its presentation at the 10th Annual Needham
Healthcare Conference on Wednesday, April 6, 2011 at 1:20 p.m.
Eastern Time. The session may be accessed through the
Company’s web site, www.regeneron.com, on the
Investor Relations page. An archived version of the
presentation will be available after the live webcast through May
6, 2011.

Regeneron is a fully integrated biopharmaceutical company that
discovers, develops, and commercializes medicines for the treatment
of serious medical conditions. In addition to ARCALYST®
(rilonacept) Injection for Subcutaneous Use, its first
commercialized product, Regeneron has therapeutic candidates in
Phase 3 clinical trials for the potential treatment of gout,
diseases of the eye (wet age-related macular degeneration and
central retinal vein occlusion), and certain cancers.
Additional therapeutic candidates developed from proprietary
Regeneron technologies for creating fully human monoclonal
antibodies are in earlier stage development programs in rheumatoid
arthritis and other inflammatory conditions, pain, cholesterol
reduction, allergic and immune conditions and cancer.
Additional information about Regeneron and recent news
releases are available on Regeneron’s web site at www.regeneron.com. Contact
Information:Michael Aberman, M.D.